Stryker Corporation (NYSE:SYK) has earned a consensus rating of “Hold” from the twenty-three research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $145.64.

A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $161.00 price objective on shares of Stryker Corporation in a research note on Monday. BidaskClub cut Stryker Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Oppenheimer Holdings, Inc. set a $148.00 target price on Stryker Corporation and gave the company a “hold” rating in a research report on Friday, July 28th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $132.00 target price on shares of Stryker Corporation in a research report on Friday, June 30th.

In other Stryker Corporation news, insider Graham A. Mclean sold 1,124 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the sale, the insider now owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Floyd sold 19,305 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total value of $2,790,730.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,429 shares of company stock valued at $3,686,927. Company insiders own 7.40% of the company’s stock.

Several hedge funds have recently bought and sold shares of SYK. Bollard Group LLC lifted its stake in Stryker Corporation by 0.4% during the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 3 shares in the last quarter. Assetmark Inc. increased its stake in Stryker Corporation by 0.3% during the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock worth $168,000 after purchasing an additional 4 shares during the period. Blue Chip Partners Inc. increased its stake in Stryker Corporation by 0.3% during the first quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock worth $234,000 after purchasing an additional 6 shares during the period. Guardian Life Insurance Co. of America increased its stake in Stryker Corporation by 0.8% during the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock worth $158,000 after purchasing an additional 9 shares during the period. Finally, FineMark National Bank & Trust increased its stake in Stryker Corporation by 0.4% during the second quarter. FineMark National Bank & Trust now owns 3,878 shares of the medical technology company’s stock worth $538,000 after purchasing an additional 15 shares during the period. Hedge funds and other institutional investors own 74.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Stryker Corporation (SYK) Given Average Recommendation of “Hold” by Brokerages” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/stryker-corporation-syk-given-average-recommendation-of-hold-by-brokerages/1603843.html.

Shares of Stryker Corporation (NYSE:SYK) traded up 1.05% during midday trading on Wednesday, reaching $143.51. The company’s stock had a trading volume of 1,053,833 shares. The stock has a 50-day moving average of $143.56 and a 200 day moving average of $138.98. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $148.84. The firm has a market capitalization of $53.68 billion, a P/E ratio of 32.03 and a beta of 0.81.

Stryker Corporation (NYSE:SYK) last released its earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The business had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. During the same quarter in the previous year, the company earned $1.39 earnings per share. The company’s quarterly revenue was up 6.1% on a year-over-year basis. Equities research analysts predict that Stryker Corporation will post $6.46 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be given a $0.425 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a yield of 1.18%. Stryker Corporation’s dividend payout ratio is currently 37.95%.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.